This trial is testing nivolumab in combination with carboplatin and paclitaxel versus the usual treatment of carboplatin and paclitaxel for anal cancer that has spread to other parts of the body.
1 Primary · 3 Secondary · Reporting Duration: Up to 2 years
Active Control
Experimental Treatment
205 Total Participants · 2 Treatment Groups
Primary Treatment: Paclitaxel · No Placebo Group · Phase 3
Age 18+ · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you:Florida | 100.0% |
18 - 65 | 100.0% |
Kaiser Permanente-San Francisco | 100.0% |
Met criteria | 50.0% |
Did not meet criteria | 50.0% |